m6A modification promotes miR-133a repression during cardiac development and hypertrophy via IGF2BP2

Area of Science:

• Molecular Biology
• Epigenetics
• Cardiovascular Biology

Background:

• N6-methyladenosine (m6A) and microRNAs (miRNAs) are key post-transcriptional regulators of gene expression.
• Both m6A and miRNAs target mRNA stability and translation, often within the 3'-untranslated regions (UTRs).
• The interplay between m6A modification and miRNA activity in cellular processes, particularly cardiac development, remains largely unexplored.

Purpose of the Study:

• To investigate the regulatory role of m6A modification in specific miRNA repression during cardiac development and hypertrophy.
• To elucidate the molecular mechanisms underlying m6A-mediated regulation of miRNA function in the heart.

Main Methods:

• Bioinformatic analysis for sequence alignment between m6A motifs and miRNA seed sequences.
• Molecular biology techniques including immunofluorescence staining, luciferase reporter assays, and m6A-RNA immunoprecipitation (m6A-RIP).
• Gene silencing experiments targeting Fto (FTO alpha-ketoglutarate dependent dioxygenase) and assessment of protein-protein interactions (AGO2-IGF2BP2).

Main Results:

• Sequence alignment identified miR-133a as a potential target inversely complementary to the m6A consensus motif.
• m6A modification was shown to promote miR-133a binding to its targets, enhancing repression via the AGO2-IGF2BP2 complex.
• Silencing Fto, an m6A-inducing enzyme, prevented m6A-mediated inhibition of miR-133a's effect on cardiac proliferation and hypertrophy.
• IGF2BP2 (Insulin-like growth factor 2 mRNA binding protein 2) physically interacted with AGO2 (Argonaute 2), increasing miR-133a accumulation on m6A-modified target sites.

Conclusions:

• m6A modification acts as a novel mechanism to promote the repression of specific miRNAs, such as miR-133a, during heart development and hypertrophy.
• The AGO2-IGF2BP2 complex plays a crucial role in mediating m6A-enhanced miRNA repression.
• Targeting m6A modification presents a potential therapeutic strategy for managing hypertrophic gene expression dysregulated by miR-133a.